Stock listing

NASDAQ:ALMS Alumis Inc. Stock

Home listing (NASDAQ) of Alumis Inc.

Follow Alumis Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:ALMS

$3.96 USD -0.43 (-9.9%)

Close on Nov 20, 2026

Past year -42.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$3.94 – $4.36 USDNov 20, 2026
Volume
1.79M sharesNov 20, 2026
Market cap
$512.6M USDAt the close on Nov 20, 2026 · price × 129.4M shares outstanding
52-week range
$3.94 – $31.35 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$24.34M USDMedian day 2.13M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Alumis Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ALMS · Home$3.96 USD-0.435 (-9.9%)1,794,304$4.235$4.36$3.935$4.395Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ALMS · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$3.96-0.435-9.9%$4.235$4.36$3.9351,794,304
$4.395-0.445-9.2%$4.92$4.95$4.352,009,295
$4.84-0.30-5.8%$5.05$5.126$4.7011,860,719
$5.14-0.46-8.2%$5.59$5.80$5.002,200,177
$5.60-0.53-8.6%$6.035$6.10$5.521,492,039
$6.13-0.49-7.4%$6.50$6.61$6.131,862,859
$6.62+0.22+3.4%$6.47$6.72$6.4251,282,890
$6.40-0.15-2.3%$6.56$6.67$6.2751,542,120
$6.55+0.52+8.6%$6.14$6.60$5.992,405,490
$6.03+0.18+3.1%$5.88$6.08$5.821,279,001
$5.85-0.70-10.7%$6.51$6.526$5.751,945,991
$6.55+0.05+0.8%$6.575$6.70$6.341,289,994
$6.50+0.12+1.9%$6.41$6.61$6.2152,562,452
$6.38-0.35-5.2%$6.81$6.81$6.2551,430,090
$6.73-0.16-2.3%$6.84$6.92$6.462,236,875
$6.89-0.24-3.4%$7.19$7.245$6.682,743,111
$7.13+0.49+7.4%$6.60$7.18$6.592,431,728
$6.64+0.13+2.0%$6.51$6.69$6.303,258,301
$6.51-0.27-4.0%$6.76$6.825$6.3751,119,816
$6.78-0.04-0.6%$6.68$6.82$6.481,230,171
$6.82+0.01+0.1%$6.72$6.945$6.6551,503,555
$6.81+0.11+1.6%$6.75$6.945$6.661,230,135
$6.70+0.36+5.7%$6.33$6.725$6.251,534,294
$6.34+0.22+3.6%$6.12$6.43$6.101,483,621
$6.12-0.19-3.0%$6.31$6.31$6.012,496,575
$6.31+0.25+4.1%$6.11$6.50$6.082,786,515
$6.06-0.50-7.6%$6.47$6.55$6.0152,298,082
$6.56-0.50-7.1%$7.01$7.01$6.5351,899,400
$7.06-0.10-1.4%$7.13$7.31$6.971,601,100
$7.16+0.19+2.7%$7.04$7.285$6.901,371,100
$6.97+0.20+3.0%$6.66$7.02$6.612,853,100
$6.77-0.16-2.3%$6.82$6.95$6.712,167,200
$6.93+0.09+1.3%$6.89$6.95$6.641,745,500
$6.84-0.01-0.1%$6.99$7.17$6.783,869,200
$6.85-0.36-5.0%$7.28$7.31$6.6352,624,700
$7.21-0.18-2.4%$7.40$7.48$7.152,130,400
$7.39+0.10+1.4%$7.35$7.555$7.151,402,000
$7.29+0.13+1.8%$7.16$7.41$7.131,667,900
$7.16+0.06+0.8%$7.10$7.22$6.832,244,700
$7.10-0.19-2.6%$7.33$7.38$7.0351,718,100
$7.29-0.15-2.0%$7.43$7.45$7.222,604,400
$7.44-0.67-8.3%$8.03$8.075$7.312,693,500
$8.11+0.21+2.7%$8.01$8.14$7.672,523,100
$7.90+0.13+1.7%$7.82$7.92$7.562,431,300
$7.77-0.05-0.6%$7.83$7.905$7.5356,384,000
$7.82-0.12-1.5%$8.03$8.11$7.7553,514,800
$7.94-0.46-5.5%$8.45$8.47$7.794,800,700
$8.40-0.82-8.9%$9.18$9.20$8.314,003,700
$9.22+0.04+0.4%$9.25$9.356$9.024,027,100
$9.18-0.72-7.3%$9.99$10.11$9.143,434,300
$9.90+0.10+1.0%$10.55$10.55$9.654,731,200
$9.80-0.78-7.4%$10.49$10.67$9.773,874,800
$10.58-0.52-4.7%$11.05$11.22$10.254,490,300
$11.10-0.26-2.3%$11.23$11.60$11.013,077,100
$11.36+1.01+9.8%$10.38$11.92$10.317,547,600
$10.35+0.88+9.3%$10.16$10.77$9.9510,377,000
$9.47-12.34-56.6%$9.93$11.06$8.7528,399,000
$21.81-0.57-2.5%$22.29$22.55$21.281,372,900
$22.38-0.83-3.6%$22.83$23.28$22.35655,000
$23.21-0.41-1.7%$23.49$24.13$23.08503,600
$23.62-0.34-1.4%$24.14$24.14$23.16642,500
$23.96+0.93+4.0%$23.52$24.04$23.24587,300
$23.03-1.14-4.7%$23.69$23.74$22.43850,600
$24.17+1.31+5.7%$22.98$24.70$22.21934,200
$22.86-1.13-4.7%$23.76$23.93$22.03949,300
Ticker
NASDAQ:ALMS
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Alumis Inc. news

Alumis Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
16 in the last 12 months · 50 in all · newest Nov 12, 2026 · oldest 2024
Decks
18 decks · latest Sep 1, 2026

Where Alumis Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ALMS · Home listing · This pageNASDAQUnited StatesUSD
BOATS:ALMSBOATSUnited StatesUSD

Valuation

EV/sales 16.1× against a median of 23.3×: 3rd lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$116.5M USD
P/E
Loss
EV/sales
16.1×
EV/EBITDA
Negative EBITDA
Price/book
1.4×
Gross margin
88.0%
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.1×
Beta vs S&P 500
1.58

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Alumis Inc. · NASDAQ:ALMSUS$512.6MUS$116.5Mn/a16.1×n/a1.4×n/a0.1×1.58
Surrozen, Inc. · NASDAQ:SRZNUS$542.5MUS$448.0Mn/a42.5×n/an/an/an/a1.64
Climb Bio, Inc. · NASDAQ:CLYMUS$539.8MUS$335.4Mn/an/an/a2.4×n/a0.0×1.44
Abbisko Cayman Limited · HKEX:2256US$518.9MUS$228.7Mn/an/an/a1.6×n/a0.2×n/a
Electra Therapeutics, Inc. · NASDAQ:ETRAUS$509.8MUS$107.3Mn/an/an/a1.3×n/a0.0×n/a
Wave Life Sciences Ltd. · NASDAQ:WVEUS$504.9MUS$74.16Mn/a1.1×n/a1.3×−296.9%0.0×1.70
Adlai Nortye Group Ltd. · NASDAQ:ANLUS$502.2MUS$297.0Mn/a59.4×n/a2.3×−710.6%0.1×1.96
Steminent Biotherapeutics, Inc. · TPEX:7729US$497.0MUS$470.5Mn/an/an/a16.2×n/a0.0×n/a
Xuanzhu Biopharmaceutical Co., Ltd. Class H · HKEX:2575US$495.2MUS$407.3Mn/a23.3×n/a2.2×−200.8%0.0×n/a
TenNor Therapeutics Suzhou Ltd. Class H · HKEX:6872US$489.2MUS$391.8Mn/an/an/a5.0×n/a0.1×n/a
Crescent Biopharma, Inc. · NASDAQ:CBIOUS$482.9MUS$196.0Mn/a13.1×n/a1.8×−727.6%0.0×0.92
Median of the othersUS$503.5MUS$316.2M23.3×2.2×−503.7%0.0×1.64

Forecasts

8 strong buy · 1 buy · 1 hold · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
30.00 USD · Analysts' mean
EPS, year to Dec 2026
-3.29 · 2 analysts
Revenue, year to Dec 2026
6.91M · 7 analysts

Team and board

Officers

OfficerRole
Martin BablerPresident, Chief Executive Officer and Chairman of the Board
John SchroerChief Financial Officer
Sanam PangaliChief Legal Officer and Corporate Secretary
Claire LangrishSVP, Head of Immunology and Translational Science
Grace HaltehSVP, Head of Quality and Regulatory
Kolbot BySVP, Head of Technical Operations
Alan B. ColowickManaging Director, AyurMaya, an affiliate of Matrix Capital Management
David M GoldsteinChief Scientific Officer
Jack DanilkowiczChief Commercial Officer
Jörn DrappaChief Medical Officer
Mark BradleyChief Development Officer
Roy HardimanChief Business and Strategy Officer
Srinivas AkkarajuFounder and Managing Member, Samsara BioCapital

Board

DirectorRole
Martin BablerPresident, Chief Executive Officer and Chairman of the Board
James B. TananbaumDirector
Lynn TetraultIndependent Board Member
Patrick MachadoIndependent Board Member
Sapna SrivastavaIndependent Board Member
Srinivas AkkarajuFounder and Managing Member, Samsara BioCapital
Zhengbin YaoDirector

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026 · After close−8.7%
Q2 2026Aug 13, 2026 · After close+3.7%
Q1 2026May 14, 2026 · After close−7.2%
Q4 2025Mar 19, 2026 · After close−1.3%
Q3 2025Nov 13, 2025 · After close+4.5%
Q2 2025Aug 13, 2025 · After close−0.7%
Q1 2025May 14, 2025 · After close+18.6%
Q4 2024Mar 19, 2025−20.3%
Q3 2024Nov 13, 2024 · After close−12.9%
Q2 2024Aug 13, 2024 · After close+1.4%
All 11 quarters
QuarterResultsShare move
Q1 2024May 29, 2024

Open Events

Decks

DeckKindSlidesDate
Technical Presentation (September 2026)Technical20 slidesSep 1, 2026
Investor Presentation (August 2026)Investor deck37 slidesAugust 2026
Investor Presentation (June 2026)Investor deck36 slidesJun 29, 2026
Technical Presentation (May 2026)Technical21 slidesMay 14, 2026
Envudeucitinib ONWARD1 and ONWARD2 Phase 3 Topline Readout Analyst and Investor Webcast (January 2026)Conference25 slidesJan 6, 2026
Corporate Update (January 2026)Corporate update25 slidesJan 6, 2026
Investor Presentation (2026)Investor deck39 slides2026
ASOPRS 2025Conference14 slidesSep 26, 2025
Investor Presentation (September 2025)Investor deck45 slidesSep 3, 2025
Jefferies Global Healthcare Conference 2025Conference27 slidesJune 2025
All 18 decks
DeckKindSlidesDate
Merger or Acquisition (March 2025)Merger or acquisition10 slidesMar 18, 2025
Technical Presentation (March 2025)Technical14 slidesMar 10, 2025
Merger or Acquisition (February 2025)Merger or acquisition18 slidesFeb 6, 2025
European Academy of Dermatology and Venereology (EADV) Congress 2024Conference12 slidesSeptember 2024
Technical Presentation (September 2024)Technical14 slidesSeptember 2024
ESOPRS 2024Conference14 slidesSeptember 2024
Technical Presentation (May 2024)Technical14 slidesMay 31, 2024
Technical Presentation (March 2024)Technical16 slidesMarch 2024

Open Decks

Financings

RaiseDate
Public offering of common stock
Closed: US$345.1M raised · US$17 a share · Morgan Stanley +5
Dealers: Morgan Stanley (lead), Leerink Partners (lead), Cantor (lead), Wells Fargo Securities (lead), Baird (co-lead), Oppenheimer & Co. (co-lead)
Jan 9, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$16.00 a share on Jun 27, 2024.

Price
US$16.00 a share
Shares offered
13,125,000 shares of common stock
Offering size
US$210 million
Underwriters' option
Up to 1,968,750 more shares
Listing
ALMS on the Nasdaq Global Select Market
Underwriters
Morgan Stanley, Leerink Partners, Cantor, Guggenheim Securities · In the order on the cover
Shares delivered
On or about Jul 1, 2024

Steps

StepWhen
Draft sent to the SEC in confidenceApr 11, 2024
Filed publiclyJun 7, 2024
Amended twiceNewest Jun 24, 2024
Shares registered with an exchangeJun 25, 2024
Declared effective by the SECJun 27, 2024
Final prospectus, with the priceJun 28, 2024

Open IPO · From the cover of the final prospectus (424B4) filed Jun 28, 2024

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022
Revenue24.1M000
Cost of revenue3.50M3.15M1.28M250.0K
Gross profit20.6M-3.15M-1.28M-250.0K
Research and development386.0M265.6M137.7M101.1M
Selling, general and administrative91.9M35.2M20.5M12.5M
Operating income-453.8M-300.8M-158.2M-113.8M
Depreciation and amortization3.50M3.15M1.28M250.0K
EBITDA-450.3M-297.6M-156.9M-113.6M
Income before tax-251.9M-294.2M-155.0M-111.9M
Income tax-8.56M00
Net income-243.3M-294.2M-155.0M-111.9M
Earnings per share, basic-2.86-10.38-72.08-14.93
Earnings per share, diluted-2.86-10.38-72.08

Balance sheet

LineFY2025FY2024FY2023FY2022
Cash and equivalents89.7M169.5M46.0M25.6M
Short-term investments218.8M118.7M2.96M67.3M
Receivables2.08M1.81M722.0K500.0K
Inventory-95.0K
Current assets318.2M306.2M53.4M102.6M
Property, plant and equipment18.2M21.0M22.4M
Total assets411.9M341.0M89.6M108.2M
Accounts payable10.1M9.62M1.12M1.72M
Current liabilities73.3M50.9M20.9M13.4M
Total debt36.9M30.7M32.6M1.78M
Total liabilities110.6M80.9M53.5M303.4M
Shareholders' equity301.3M260.1M-339.3M-195.2M
Shares outstanding850.3M28.3M51.8M7.50M

Cash flow

LineFY2025FY2024FY2023FY2022
Cash from operations-369.5M-255.1M-130.0M-107.7M
Capital spending-653.0K-1.73M-4.50M-2.41M
Free cash flow-370.2M-256.8M-134.5M-110.1M
Cash from investing287.9M-113.8M60.5M-68.8M
Cash from financing2.07M492.4M89.7M101.6M
Share buybacks-17.0K-6.00K-64.0K
Change in cash-79.6M123.5M20.2M-74.8M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportNov 12, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2026Big-stake noticeSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
4 · Change in ownershipSep 9, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportSep 1, 2026Current reportSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
8-K · Current reportAug 13, 2026ResultsSEC
8-K · Current reportAug 10, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeAug 6, 2026Big-stake noticeSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJul 27, 2026Big-stake noticeSEC
4 · Change in ownershipJul 8, 2026Insider tradeSEC
144 · Notice of proposed saleJul 6, 2026Other filingsSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 2, 2026Big-stake noticeSEC
8-K · Current reportJul 2, 2026Meeting outcomeSEC
8-K · Current reportJun 29, 2026Current reportSEC
4 · Change in ownershipMay 27, 2026Insider tradeSEC
ARS · Annual report to shareholdersMay 18, 2026Annual reportSEC
DEFA14A · Additional proxy materialMay 18, 2026Meeting noticeSEC
DEF 14A · Proxy statementMay 18, 2026Meeting noticeSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
8-K · Current reportMay 14, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeApr 7, 2026Big-stake noticeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 3, 2026Big-stake noticeSEC
8-K · Current reportMar 30, 2026Current reportSEC
S-3ASR · Registration statementMar 19, 2026Offer documentSEC
10-K · Annual reportMar 19, 2026Annual reportSEC
8-K · Current reportMar 19, 2026ResultsSEC
5 · Annual statement of ownershipFeb 11, 2026Insider tradeSEC
S-8 · Registration statement for employee plansJan 30, 2026Offer documentSEC
4 · Change in ownershipJan 28, 2026Insider tradeSEC
4 · Change in ownershipJan 28, 2026Insider tradeSEC
4 · Change in ownershipJan 28, 2026Insider tradeSEC
4 · Change in ownershipJan 28, 2026Insider tradeSEC
4 · Change in ownershipJan 28, 2026Insider tradeSEC
4 · Change in ownershipJan 28, 2026Insider tradeSEC
4 · Change in ownershipJan 28, 2026Insider tradeSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 13, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 12, 2026Big-stake noticeSEC
4 · Change in ownershipJan 12, 2026Insider tradeSEC
4 · Change in ownershipJan 12, 2026Insider tradeSEC
4 · Change in ownershipJan 12, 2026Insider tradeSEC
8-K · Current reportJan 9, 2026ResultsSEC
424B5 · ProspectusJan 8, 2026Offer documentSEC
424B5 · ProspectusJan 6, 2026Offer documentSEC
8-K · Current reportJan 6, 2026Current reportSEC
8-K · Current reportJan 2, 2026Current reportSEC
4 · Change in ownershipDec 9, 2025Insider tradeSEC
4 · Change in ownershipDec 4, 2025Insider tradeSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
4 · Change in ownershipNov 25, 2025Insider tradeSEC
4 · Change in ownershipNov 25, 2025Insider tradeSEC
4 · Change in ownershipNov 25, 2025Insider tradeSEC
SCHEDULE 13D · Big-stake noticeNov 24, 2025Big-stake noticeSEC
4 · Change in ownershipNov 24, 2025Insider tradeSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
4 · Change in ownershipNov 17, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 17, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 17, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
8-K · Current reportNov 13, 2025ResultsSEC
8-K · Current reportSep 3, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveAug 20, 2025Other filingsSEC
CORRESP · Letter to the SECAug 15, 2025Other filingsSEC
10-Q · Quarterly reportAug 13, 2025Quarterly reportSEC
8-K · Current reportAug 13, 2025ResultsSEC
8-K · Current reportAug 4, 2025Meeting outcomeSEC
4 · Change in ownershipAug 1, 2025Insider tradeSEC
4 · Change in ownershipAug 1, 2025Insider tradeSEC
4 · Change in ownershipAug 1, 2025Insider tradeSEC
4 · Change in ownershipAug 1, 2025Insider tradeSEC
4 · Change in ownershipAug 1, 2025Insider tradeSEC
4 · Change in ownershipJul 31, 2025Insider tradeSEC
4 · Change in ownershipJul 31, 2025Insider tradeSEC
4 · Change in ownershipJul 31, 2025Insider tradeSEC
4 · Change in ownershipJul 31, 2025Insider tradeSEC
4 · Change in ownershipJul 31, 2025Insider tradeSEC
4 · Change in ownershipJul 31, 2025Insider tradeSEC
4 · Change in ownershipJul 31, 2025Insider tradeSEC
4 · Change in ownershipJul 31, 2025Insider tradeSEC
4 · Change in ownershipJul 14, 2025Insider tradeSEC
3 · Initial statement of ownershipJul 14, 2025Insider tradeSEC
UPLOAD · Letter from the SECJul 9, 2025Other filingsSEC
S-3 · Registration statementJul 3, 2025Offer documentSEC
8-K/A · Current report, amendedJun 30, 2025Current reportSEC
ARS · Annual report to shareholdersJun 16, 2025Annual reportSEC
DEFA14A · Additional proxy materialJun 16, 2025Meeting noticeSEC
DEF 14A · Proxy statementJun 16, 2025Meeting noticeSEC
S-8 · Registration statement for employee plansJun 10, 2025Offer documentSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 10, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 23, 2025Big-stake noticeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 23, 2025Big-stake noticeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
3 · Initial statement of ownershipMay 23, 2025Insider tradeSEC
8-K · Current reportMay 21, 2025Acquisition or disposalSEC
8-K · Current reportMay 19, 2025Meeting outcomeSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
8-K · Current reportMay 14, 2025ResultsSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 7, 2025Big-stake noticeSEC
4 · Change in ownershipMay 6, 2025Insider tradeSEC
4 · Change in ownershipMay 6, 2025Insider tradeSEC
4 · Change in ownershipMay 6, 2025Insider tradeSEC
4 · Change in ownershipMay 6, 2025Insider tradeSEC
425Apr 29, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveApr 24, 2025Other filingsSEC
424B3 · ProspectusApr 23, 2025Offer documentSEC
10-K/A · Annual report, amendedApr 23, 2025Annual reportSEC
CORRESP · Letter to the SECApr 22, 2025Other filingsSEC
UPLOAD · Letter from the SECApr 22, 2025Other filingsSEC
S-4 · Registration statementApr 21, 2025Offer documentSEC
425Apr 21, 2025Other filingsSEC
425Apr 21, 2025Other filingsSEC
425Apr 21, 2025Other filingsSEC
8-K · Current reportApr 21, 2025Material contractSEC
EFFECT · Notice that a registration is effectiveApr 7, 2025Other filingsSEC
425Apr 4, 2025Other filingsSEC
424B3 · ProspectusApr 4, 2025Offer documentSEC
4 · Change in ownershipApr 3, 2025Insider tradeSEC
4 · Change in ownershipApr 3, 2025Insider tradeSEC
CORRESP · Letter to the SECApr 2, 2025Other filingsSEC
S-4/A · Registration statement, amendedApr 2, 2025Offer documentSEC
S-4 · Registration statementMar 27, 2025Offer documentSEC
425Mar 25, 2025Other filingsSEC
8-K · Current reportMar 25, 2025Current reportSEC
S-8 · Registration statement for employee plansMar 19, 2025Offer documentSEC
425Mar 19, 2025Other filingsSEC
10-K · Annual reportMar 19, 2025Annual reportSEC
8-K · Current reportMar 19, 2025ResultsSEC
8-K · Current reportMar 18, 2025Current reportSEC
425Mar 18, 2025Other filingsSEC
425Mar 11, 2025Other filingsSEC
8-K · Current reportMar 10, 2025Current reportSEC
425Mar 6, 2025Other filingsSEC
425Mar 4, 2025Other filingsSEC
8-K · Current reportMar 4, 2025Current reportSEC
8-K · Current reportFeb 21, 2025Management or board changeSEC
4 · Change in ownershipFeb 20, 2025Insider tradeSEC
4 · Change in ownershipFeb 20, 2025Insider tradeSEC
4 · Change in ownershipFeb 20, 2025Insider tradeSEC
4 · Change in ownershipFeb 20, 2025Insider tradeSEC
4 · Change in ownershipFeb 20, 2025Insider tradeSEC
4 · Change in ownershipFeb 20, 2025Insider tradeSEC
4 · Change in ownershipFeb 20, 2025Insider tradeSEC
4 · Change in ownershipFeb 20, 2025Insider tradeSEC
UPLOAD · Letter from the SECFeb 19, 2025Other filingsSEC
DRS · Draft registration statementFeb 14, 2025Offer documentSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 10, 2025Big-stake noticeSEC
425Feb 7, 2025Other filingsSEC
425Feb 6, 2025Other filingsSEC
425Feb 6, 2025Other filingsSEC
425Feb 6, 2025Other filingsSEC
8-K · Current reportFeb 6, 2025ResultsSEC
UPLOAD · Letter from the SECDec 3, 2024Other filingsSEC
8-K · Current reportNov 25, 2024Current reportSEC
10-Q · Quarterly reportNov 13, 2024Quarterly reportSEC
8-K · Current reportNov 13, 2024ResultsSEC
SC 13D · Big-stake noticeAug 27, 2024Big-stake noticeSEC
4/A · Change in ownership, amendedAug 27, 2024Insider tradeSEC
10-Q · Quarterly reportAug 13, 2024Quarterly reportSEC
8-K · Current reportAug 13, 2024ResultsSEC
DJul 24, 2024Other filingsSEC
8-K · Current reportJul 18, 2024Current reportSEC
SC 13G · Big-stake noticeJul 11, 2024Big-stake noticeSEC
SC 13D · Big-stake noticeJul 5, 2024Big-stake noticeSEC
4 · Change in ownershipJul 3, 2024Insider tradeSEC
4 · Change in ownershipJul 3, 2024Insider tradeSEC
4 · Change in ownershipJul 3, 2024Insider tradeSEC
SC 13D · Big-stake noticeJul 3, 2024Big-stake noticeSEC
4 · Change in ownershipJul 3, 2024Insider tradeSEC
8-K · Current reportJul 3, 2024Material contractSEC
SEC STAFF LETTERJul 2, 2024Other filingsSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC

This page holds 200 of 250 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Alumis Inc.’s releases · as of Jan 9, 2026

Common shares
129,435,239
Fully diluted
129,435,239

Fully diluted

LineShares
Common shares129,435,239

Share count over time

CountShares
Nov 22, 2026129,435,239

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
AyurMaya Capital Management Company, LP15.1M11.7%US$112MSep 30, 2026
BlackRock8.58M6.6%US$63.4MSep 30, 2026
Deep Track Capital, LP7.47M5.8%US$55.2MSep 30, 2026
Samsara Biocapital, LLC7.24M5.6%US$53.5MSep 30, 2026
Vanguard6M4.6%US$44.4MSep 30, 2026
Foresite Capital Management V, LLC5.9M4.6%US$43.6MSep 30, 2026
Nextech Invest Ltd.4.55M3.5%US$33.6MSep 30, 2026
Foresite Capital Management VI LLC4.25M3.3%US$31.4MSep 30, 2026
venBio Partners LLC4.19M3.2%US$31MSep 30, 2026
Millennium3.33M2.6%US$24.6MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
State Street2.95M2.3%US$21.8MSep 30, 2026
Saturn V Capital Management LP2.86M2.2%US$21.1MSep 30, 2026
Citadel2.39M1.8%US$17.6MSep 30, 2026
Morgan Stanley2.16M1.7%US$16MSep 30, 2026
Cormorant Asset Management, LP2.08M1.6%US$15.3MSep 30, 2026
Sr One Capital Management, LP1.96M1.5%US$14.5MSep 30, 2026
Qube Research & Technologies Ltd1.91M1.5%US$14.1MSep 30, 2026
Geode Capital1.79M1.4%US$13.2MSep 30, 2026
Two Sigma1.33M1.0%US$9.83MSep 30, 2026
Novo Holdings A/S1.25M0.97%US$9.24MSep 30, 2026
Citigroup Inc1.22M0.94%US$9.02MSep 30, 2026
Susquehanna1.2M0.93%US$8.85MSep 30, 2026
Marshall Wace, LLP1.06M0.82%US$7.85MSep 30, 2026
T. Rowe Price1.02M0.79%US$7.57MSep 30, 2026
Opaleye Management Inc.1M0.77%US$7.4MSep 30, 2026
Goldman Sachs920K0.71%US$6.8MSep 30, 2026
Principal795K0.61%US$5.87MSep 30, 2026
Schwab782K0.60%US$5.78MSep 30, 2026
Elmind Capital, LP750K0.58%US$5.54MSep 30, 2026
Northern Trust728K0.56%US$5.38MSep 30, 2026
AQR Capital Management LLC707K0.55%US$5.22MSep 30, 2026
Integral Health Asset Management, LLC700K0.54%US$5.17MSep 30, 2026
UBS677K0.52%US$5.01MSep 30, 2026
Pictet Asset Management Holding SA647K0.50%US$4.78MSep 30, 2026
Orbimed Advisors LLC548K0.42%US$4.05MSep 30, 2026
Trexquant Investment LP515K0.40%US$3.8MSep 30, 2026
Weiss Asset Management LP469K0.36%US$3.46MSep 30, 2026
JPMorgan405K0.31%US$2.98MSep 30, 2026
Kera Capital Partners, Inc.404K0.31%US$2.71MSep 30, 2026
Spruce Street Capital LP393K0.30%US$2.9MSep 30, 2026
Jane Street377K0.29%US$2.78MSep 30, 2026
Occudo Quantitative Strategies LP376K0.29%US$2.78MSep 30, 2026
Barclays371K0.29%US$2.74MSep 30, 2026
Dimensional345K0.27%US$2.55MSep 30, 2026
First Trust324K0.25%US$2.4MSep 30, 2026
D. E. Shaw & Co., Inc.311K0.24%US$2.3MSep 30, 2026
Caption Management, LLC303K0.23%US$2.24MSep 30, 2026
Hudson Bay Capital Management LP285K0.22%US$2.11MSep 30, 2026
Exome Asset Management LLC282K0.22%US$2.09MSep 30, 2026
Towerview LLC278K0.21%US$2.05MSep 30, 2026

This page holds 50 of 193 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund3.14M2.4%US$88.4MJun 30, 2026
iShares Russell 2000 ETF2.02M1.6%US$56.9MJun 30, 2026
T. Rowe Price New Horizons Fund, Inc.1.37M1.1%US$38.5MJun 30, 2026
Fidelity Small Cap Growth Fund1.1M0.85%US$31.2MJul 31, 2026
Fidelity Stock Selector Small Cap Fund1.1M0.85%US$31.2MJul 31, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund1.09M0.84%US$30.6MJun 30, 2026
Vanguard Extended Market Index Fund977K0.75%US$27.5MJun 30, 2026
Fidelity Advisor Biotechnology Fund947K0.73%US$26.7MJul 31, 2026
Fidelity Small Cap Index Fund864K0.67%US$24.4MJul 31, 2026
iShares Russell 2000 Growth ETF682K0.53%US$19.2MJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Fidelity Series Small Cap Opportunities Fund633K0.49%US$17.9MJul 31, 2026
Select Biotechnology Portfolio620K0.48%US$13.4MMay 31, 2026
T. Rowe Price Health Sciences Fund, Inc.595K0.46%US$16.7MJun 30, 2026
iShares Biotechnology ETF594K0.46%US$16.7MJun 30, 2026
Fidelity Small Cap Growth K6 Fund572K0.44%US$16.2MJul 31, 2026
Fidelity Advisor Health Care Fund460K0.36%US$13MJul 31, 2026
Fidelity Extended Market Index Fund419K0.32%US$9.06MMay 31, 2026
Invesco Main Street Small Cap Fund409K0.32%US$11.5MJun 30, 2026
SmallCap Fund404K0.31%US$11.4MJul 31, 2026
Schwab U.S. Small-Cap ETF390K0.30%US$8.42MMay 31, 2026
Vanguard Explorer Fund361K0.28%US$10.2MJul 31, 2026
Vanguard Russell 2000 Index Fund352K0.27%US$7.6MMay 31, 2026
Fidelity Enhanced Small Cap Core ETF346K0.27%US$9.74MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF326K0.25%US$9.17MJun 30, 2026
Select Health Care Portfolio301K0.23%US$6.51MMay 31, 2026
BlackRock Health Sciences Opportunities Portfolio294K0.23%US$6.34MMay 29, 2026
Fidelity Small Cap Value Fund250K0.19%US$7.06MJul 31, 2026
Invesco V.I. Main Street Small Cap Fund224K0.17%US$6.31MJun 30, 2026
iShares U.S. Pharmaceuticals ETF222K0.17%US$6.23MJun 30, 2026
Fidelity Small Cap Discovery Fund217K0.17%US$6.14MJul 31, 2026
Fidelity Series Small Cap Core Fund206K0.16%US$5.83MJul 31, 2026
Royce Small-Cap Fund197K0.15%US$5.55MJun 30, 2026
Vanguard Health Care Index Fund194K0.15%US$4.18MMay 31, 2026
Schwab Small-Cap Index Fund192K0.15%US$5.42MJul 31, 2026
Fidelity Series Small Cap Discovery Fund186K0.14%US$5.26MJul 31, 2026
First Trust Small Cap Growth AlphaDEX Fund184K0.14%US$5.19MJul 31, 2026
T. Rowe Price Small-Mid Cap ETF180K0.14%US$5.07MJun 30, 2026
Fidelity Total Market Index Fund157K0.12%US$3.39MMay 31, 2026
VIP Health Care Portfolio146K0.11%US$4.11MJun 30, 2026
Master Small Cap Index Series141K0.11%US$3.97MJun 30, 2026
Optimum Small-Mid Cap Growth Fund135K0.10%US$3.79MJun 30, 2026
Fidelity Small Cap Stock Fund133K0.10%US$3.75MJul 31, 2026
Invesco Dorsey Wright SmallCap Momentum ETF131K0.10%US$2.82MMay 31, 2026
T. Rowe Price Integrated U.S. Small-Mid Cap Core Equity Fund128K0.10%US$3.61MJun 30, 2026
Vanguard U.S. Momentum Factor ETF126K0.10%US$2.73MMay 31, 2026
Fidelity Series Total Market Index Fund123K0.10%US$2.66MMay 31, 2026
VictoryShares US Small Mid Cap Value Momentum ETF123K0.09%US$3.45MJun 30, 2026
T.Rowe Price Small Cap Growth Portfolio121K0.09%US$3.42MJun 30, 2026
iShares Core S&P Total U.S. Stock Market ETF112K0.09%US$3.17MJun 30, 2026
Invesco RAFI US 1500 Small-Mid ETF99,8890.08%US$2.82MJul 31, 2026

This page holds 50 of 212 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Hardiman Roy C.
Officer: Chief Business & Strategy Ofcr
Sale652USD 6.52US$4,251Nov 2, 2026
Schroer John R.
Officer: Chief Financial Officer
Sale794USD 6.52US$5,177Nov 2, 2026
Goldstein David M
Officer: Chief Scientific Officer
Sale629USD 6.52US$4,101Nov 2, 2026
Drappa Jorn
Officer: Chief Medical Officer
Sale593USD 6.52US$3,866Nov 2, 2026
Bradley Mark Christopher
Officer: Chief Development Officer
Sale623USD 6.52US$4,062Nov 2, 2026
Pangali Sanam
Officer: Chief Legal Officer
Sale332USD 6.52US$2,165Nov 2, 2026
Srinivas Akkaraju
Director
Sale48,066USD 10.55US$507KSep 8, 2026
Srinivas Akkaraju
Director
Sale48,065USD 10.55US$507KSep 8, 2026
Srinivas Akkaraju
Director
Buy273,291USD 10.63US$2.91MSep 8, 2026
Srinivas Akkaraju
Director
Buy273,290USD 10.63US$2.91MSep 8, 2026
All 18 trades
TradeTradeSharesPriceValueDate
Srinivas Akkaraju
Director
Buy220,070USD 11.17US$2.46MSep 4, 2026
Hardiman Roy C.
Officer: Chief Business & Strategy Ofcr
Sale2,692USD 26.37US$70,988Aug 3, 2026
Schroer John R.
Officer: Chief Financial Officer
Sale3,282USD 26.37US$86,546Aug 3, 2026
Goldstein David M
Officer: Chief Scientific Officer
Sale2,596USD 26.37US$68,457Aug 3, 2026
Drappa Jorn
Officer: Chief Medical Officer
Sale2,447USD 26.37US$64,527Aug 3, 2026
Bradley Mark Christopher
Officer: Chief Development Officer
Sale2,572USD 26.37US$67,824Aug 3, 2026
Pangali Sanam
Officer: Chief Legal Officer
Sale1,364USD 26.37US$35,969Aug 3, 2026
Pangali Sanam
Officer: Chief Legal Officer
Sale5,000USD 28.00US$140KJul 6, 2026

Big stakes

StakeStakeSharesDateFiling
James B. Tananbaum12.70%15.7MApr 1, 2026Schedule 13D
AyurMaya Capital Management Company, LP12.30%15.1MMay 14, 2026Schedule 13D
Deep Track Capital, LP5.98%7.36MMar 30, 2026Schedule 13G
BlackRock, Inc.5.70%7.07MJun 30, 2026Schedule 13G
Srinivas Akkaraju5.40%6.35MJan 9, 2026Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Patrick Machado
Other companies: Xenon Pharmaceuticals Inc. (Director · Since at least Nov 5, 2020); Arcus Biosciences, Inc. (Board Member · Since at least Dec 10, 2019); Adverum Biotechnologies Inc (Director · Since at least Mar 14, 2017); Turnstone Biologics Corp. (Director · Jul 20, 2023 – Jul 20, 2023 · Past); Acelyrin, Inc. (Director · May 4, 2023 – May 21, 2025 · Past); Roivant Sciences Ltd. (Director · Oct 1, 2021 – Oct 1, 2021 · Past); Principia Biopharma Inc (Director · Jun 11, 2019 – Sep 28, 2020 · Past); Turning Point Therapeutics Inc (Director · May 13, 2019 – Aug 17, 2022 · Past); Endocyte Inc (Director · Feb 27, 2018 – Dec 21, 2018 · Past); Sio Gene Therapies Inc (Director · Jul 17, 2017 – Jul 17, 2017 · Past); Rocket Pharmaceuticals, Inc. (Director · Aug 17, 2016 – Jun 20, 2017 · Past); Scynexis, Inc. (Director · Sep 24, 2015 – Jan 2, 2019 · Past); Chimerix Inc (Director · Jun 20, 2014 – Jun 9, 2023 · Past); Medivation Inc (Director · Jun 5, 2007 – Sep 28, 2016 · Past)
Independent Board Member · Since at least Jun 27, 2024
Srinivas Akkaraju
Other companies: Kalaris Therapeutics, Inc. (Director · Since at least Mar 18, 2025); vTv Therapeutics Inc. (Director · Since at least Feb 23, 2024); Mineralys Therapeutics, Inc. (Board Member · Since at least Feb 9, 2023); Scholar Rock Holding Corporation (Director · Since at least Jul 26, 2022); Jiya Acquisition Corp (Director · Sep 23, 2022 – Sep 23, 2022 · Past); Syros Pharmaceuticals, Inc. (Director · Jun 1, 2022 – Sep 16, 2024 · Past); Aduro Biotech Inc (Director · May 26, 2022 – Aug 11, 2023 · Past); Intercept Pharmaceuticals Inc (Director · May 25, 2022 – Nov 8, 2023 · Past)
Founder and Managing Member, Samsara BioCapital · Since at least Jun 27, 2024
David E Goel
Other companies: Acelyrin, Inc. (Director · May 4, 2023 – May 21, 2025 · Past); Zentalis Pharmaceuticals, Inc. (Director · Apr 3, 2020 – Apr 3, 2020 · Past); Adaptive Biotechnologies Corporation (Director · Jun 26, 2019 – Feb 15, 2021 · Past); Popular, Inc. (Director · Feb 12, 2012 – May 8, 2018 · Past)
Director · Jun 27, 2024 – May 21, 2025 · Past
Martin Babler
Other companies: MapLight Therapeutics, Inc. (Member of the Audit Committee · Since at least Jun 23, 2026); 89bio Inc (Director · Since at least Apr 13, 2024); Prelude Therapeutics Incorporated (Director · Since at least Jun 17, 2022); Neurogene Inc. (Director · May 12, 2022 – Jun 8, 2023 · Past)
President, CEO and Chairman, Director · Since at least Jun 27, 2024
Lynn A. Tetrault
Other companies: NeoGenomics, Inc. (Director · Since at least Jun 2, 2021); Rhythm Pharmaceuticals, Inc. (Director · Since at least Dec 9, 2020); Acelyrin, Inc. (Director · Dec 18, 2023 – May 21, 2025 · Past)
Director · Since at least May 21, 2025
Sapna Srivastava
Other companies: Nuvalent, Inc. (Director · Since at least Jun 18, 2025); Aura Biosciences, Inc. (Director · Since at least Jun 17, 2025); Tourmaline Bio Inc. (Director · Since at least Jun 4, 2025)
Director · Since at least Jul 30, 2025
David M Goldstein
Other companies: Principia Biopharma Inc (Chief Scientific Officer · Sep 13, 2018 – Sep 28, 2020 · Past)
Chief Scientific Officer · Since at least Jun 27, 2024
Jim Tananbaum
Other companies: Latigo Biotherapeutics, Inc. (Director · Since at least Aug 10, 2026)
Director · Since at least Apr 1, 2026
Sanam Pangali
Other companies: Acelyrin, Inc. (CLO & Head of People · May 9, 2024 – May 23, 2024 · Past)
Chief Legal Officer · Since at least Jul 4, 2025
Alan B. ColowickManaging Director, AyurMaya, an affiliate of Matrix Capital Management · Since at least Nov 5, 2026
All 19 people
PersonSeat
Claire LangrishSVP, Head of Immunology and Translational Science · Since at least Nov 4, 2026
Grace HaltehSVP, Head of Quality and Regulatory · Since at least Nov 4, 2026
Jack DanilkowiczChief Commercial Officer · Since at least Jan 28, 2025
John SchroerChief Financial Officer · Since at least Aug 3, 2026
Jörn DrappaChief Medical Officer · Since at least May 22, 2026
Kolbot BySVP, Head of Technical Operations · Since at least Nov 4, 2026
Mark BradleyChief Development Officer · Since at least Jul 29, 2025
Roy HardimanChief Business and Strategy Officer · Since at least Jan 28, 2025
Zhengbin YaoDirector · Since at least Jul 2, 2026

Open People

Log in to ask 6ix AI your own questions about Alumis Inc.